SITC 2018 - Society for Immunotherapy of Cancer 33rd Annual Meeting
Nov 07 - Nov 11, 2018 | Washington, DCUS
LARVOL is not affiliated with Society for Immunotherapy of Cancer 33rd Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 144 abstracts linked to Trials
Comparison of peripheral immune response during chemoradiotherapy (CRT) with and without PD-1 blockade in patients with head and neck squamous cell carcinoma (HNSCC)
Deep learning-based PD-L1 tumor cell (TC) scoring improves survival prediction compared to pathologists on durvalumab-treated NSCLC patients
Immune response in patients treated with autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC from the phase I, open label, dose escalation and cohort expansion study
Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence
Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors
Phase 1/2 study of mogamulizumab (anti-CCR4), to deplete regulatory T-cells, in combination with PD-1 checkpoint inhibitor nivolumab in subjects with locally advanced or metastatic solid tumors
Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab
Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma
HLA class I subtypes are associated with immunerelated adverse events in patients with melanoma treated with ipilimumab
Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma
Peripheral immune monitoring identifies biomarkers of response and toxicity after neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma
Characterization of changes in tumor immune microenvironment after treatment with neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma
Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab
Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of Tcell activation (VISTA) and PD-L1
Durvalumab treatment-induced transcriptional changes in the tumor microenvironment associated with longer survival in patients with late stage Non- Small Cell Lung Cancer (NSCLC)